According to Zacks, “Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company involved in the treatment of neurodegenerative diseases. The company’s product candidate includes YTX-7739.Yumanity Therapeutics Inc., formerly known as Proteostasis Therapeutics Inc., is based in BOSTON. “
Shares of NASDAQ:YMTX traded up $0.18 during midday trading on Friday, reaching $1.20. 48,592 shares of the company’s stock traded hands, compared to its average volume of 42,166. The company has a fifty day simple moving average of $1.33 and a two-hundred day simple moving average of $2.71. Yumanity Therapeutics has a 1 year low of $0.95 and a 1 year high of $16.89. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.88 and a current ratio of 1.88. The company has a market cap of $13.02 million, a P/E ratio of -0.28 and a beta of 0.88.
Institutional investors have recently added to or reduced their stakes in the stock. Altium Capital Management LP grew its position in shares of Yumanity Therapeutics by 58.5% in the 3rd quarter. Altium Capital Management LP now owns 196,000 shares of the company’s stock worth $2,023,000 after acquiring an additional 72,307 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Yumanity Therapeutics by 168.7% in the 4th quarter. Renaissance Technologies LLC now owns 96,520 shares of the company’s stock worth $286,000 after acquiring an additional 60,601 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Yumanity Therapeutics by 272.7% in the 4th quarter. Acadian Asset Management LLC now owns 75,928 shares of the company’s stock worth $223,000 after acquiring an additional 55,557 shares during the last quarter. Stonepine Capital Management LLC grew its holdings in shares of Yumanity Therapeutics by 9.0% during the third quarter. Stonepine Capital Management LLC now owns 481,692 shares of the company’s stock valued at $4,971,000 after buying an additional 39,733 shares in the last quarter. Finally, Ensign Peak Advisors Inc purchased a new position in Yumanity Therapeutics in the third quarter valued at about $349,000. Hedge funds and other institutional investors own 27.71% of the company’s stock.
About Yumanity Therapeutics (Get Rating)
Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.
- Get a free copy of the StockNews.com research report on Yumanity Therapeutics (YMTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.